Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Among various abstracts presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, June 2010, four interesting abstracts focusing on pancreatic cancer merit further discussion in this post-ASCO commentary as they potentially provide insight to clinicians and hope to patients. These abstracts point to the future of pancreatic cancer management through identification of molecular targets and prognostic factors to overcome the limits of efficacious chemotherapy delivery.
Merika
Eirini
E
West London Renal and Transplant Centre, Hammersmith Hospital, Imperial College London, London, United Kingdom.
Syrigos
Konstantinos N
KN
Saif
Muhammad Wasif
MW
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D002641:Chicago; D003226:Congresses as Topic; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000639:trends; D008958:Models, Molecular; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods*; D012955:Societies, Medical / Q000458:organization & administration; D014481:United States
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor